Literature DB >> 11588613

Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses.

A J Law1, J F Deakin.   

Abstract

The psychotomimetic properties of NMDA glutamate receptor antagonists suggest there may be disease related changes of this receptor in schizophrenia. Using in situ hybridisation histochemistry (ISHH), we measured mRNA for the obligatory NMDAR1 subunit of the NMDA glutamate receptor in post-mortem samples of hippocampus from schizophrenics, depressives, bipolar patients and normal controls. A significant main effect of diagnosis was observed in the dentate gyrus (ANOVA, p = 0.004) and a trend in the CA3 region (ANOVA, p = 0.06), with all psychiatric groups having reduced NMDAR1 mRNA levels compared to normal controls. In contrast to the affectively ill groups, the reductions in schizophrenics were more pronounced in the left side compared to the right. Expression of poly A mRNA also showed left-sided losses in the dentate gyrus in schizophrenia but reductions in NMDAR1 remained significant when expressed as a ratio of poly A. The findings confirm a recent report of reduced hippocampal NMDAR1 mRNA in schizophrenia. However, our new evidence suggests that this is a feature of both affective and schizophrenic disorders and that schizophrenia is distinguished from the others by left-sided reductions in hippocampal NMDAR1 gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11588613     DOI: 10.1097/00001756-200109170-00043

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  71 in total

Review 1.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 2.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

3.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

Authors:  Robert E McCullumsmith; Lars V Kristiansen; Monica Beneyto; Elizabeth Scarr; Brian Dean; James H Meador-Woodruff
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

Review 4.  Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling.

Authors:  Carol A Tamminga; Sarah Southcott; Carolyn Sacco; Anthony D Wagner; Subroto Ghose
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

5.  Meta-analysis of 12 genomic studies in bipolar disorder.

Authors:  Michael Elashoff; Brandon W Higgs; Robert H Yolken; Michael B Knable; Serge Weis; Maree J Webster; Beata M Barci; E Fuller Torrey
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 6.  Targeting the hippocampal mossy fiber synapse for the treatment of psychiatric disorders.

Authors:  Katsunori Kobayashi
Journal:  Mol Neurobiol       Date:  2009-01-08       Impact factor: 5.590

7.  Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.

Authors:  C Kiselycznyk; P Svenningsson; E Delpire; A Holmes
Journal:  Neuroscience       Date:  2011-06-23       Impact factor: 3.590

8.  Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

Authors:  Scott A Schobel; Nashid H Chaudhury; Usman A Khan; Beatriz Paniagua; Martin A Styner; Iris Asllani; Benjamin P Inbar; Cheryl M Corcoran; Jeffrey A Lieberman; Holly Moore; Scott A Small
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

9.  NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test.

Authors:  Mehdi Ghasemi; Laleh Montaser-Kouhsari; Hamed Shafaroodi; Behtash Ghazi Nezami; Farzad Ebrahimi; Ahmad Reza Dehpour
Journal:  Psychopharmacology (Berl)       Date:  2009-07-16       Impact factor: 4.530

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.